Snapshot from Jul 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / United States / Gilead Sciences

United States & Gilead Sciences

3 shared events · Importance 7 · Last updated Jul 04, 2026

Importance
7
Shared Events
3
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (3)
59
Tech
Ebola Treatment Trial Begins DRC
United States: The United States government has funded research for MBP134 and owns doses of the drug, contributing to the clinical trial efforts.
Gilead Sciences: Gilead Sciences is the developer of remdesivir, one of the antiviral drugs being evaluated in the clinical trial for Ebola. The company has donated doses of the drug for the study.
Apr 20, 2026 · 67 articles
0
Tech
Africa Rolls Out Lenacapavir HIV Prevention
Dec 01, 2025 · 6 articles
0
Regulatory
Trump Secures Drug Price Deals
Gilead Sciences: Gilead Sciences is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
NEWSDESK
Explore this relationship live

Track how United States and Gilead Sciences interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.